		Technical Data
G2032-28B	GFAP (Glial Fibrillary Acidic Protein)

Description:
Glial Fibrillary Acidic Protein (GFAP) is specific to astrocytes (i.e., glial cells) and ependymal cells of the central nervous system. Antibody to GFAP is useful in differentiating primary gliomas from metastatic lesions in the brain and for documenting astrocytic differentiation in tumors outside the CNS.

Applications:
Suitable for use in Immunofluorescence, Western Blot and Immunohistochemistry. Other applications have not been tested.

Recommended Dilution:
Western Blot: 1-2ug/ml for 2hrs at RT
Immunohistochemistry (Formalin/paraffin): 1-2ug/ml for 30 min at RT. Note: No special pretreatment required prior to staining of formalin-fixed, paraffin-embedded sections.
Optimal dilutions to be determined by the researcher.

Positive Control:
IMR-5 cells, Brain or astrocytoma

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Type	Isotype	Clone	Grade
Mab	IgG1	3F186	Affinity Purified

Size		Storage	Shipping	Source	Host
500ul		-20°C	Blue Ice	Human	Mouse

Concentration:

~0.2mg/ml

Immunogen:

Glial Fibrillary Acidic Protein (51-52kD). Cellular Localization: Cytoplasmic

Purity:

Purified by Protein G affinity chromatography.

Form

Supplied as a liquid in PBS, pH 7.4, 0.2% BSA, 0.09% sodium azide. Also available without BSA and azide. See G2032-28BX.

Specificity:

Recognizes human GFAP. Stains astrocytes, glial cells, ependymal cells and their corresponding tumors. Does not stain many types of neural tumors such as neuroblastomas, Schwannomas and extra-CNS tumors. Species Crossreactivity: porcine, rat and chicken.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

1. Debus E, et. al. Differentiation, 1983, 25(2): 193-203. 2. Yachnis AT; et al. Journal of Comparative Neurology, 1993, 334(3): 356-69. 3. Trivino A; et al. Vision Res, 1992, 32(9): 1601-7.